Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 393,681
  • Shares Outstanding, K 54,754
  • Annual Sales, $ 0 K
  • Annual Income, $ -60,460 K
  • 60-Month Beta 2.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.37
  • Low Estimate -0.38
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.04 +19.04%
on 07/29/20
8.21 -12.42%
on 07/09/20
-0.27 (-3.62%)
since 07/07/20
3-Month
3.56 +101.97%
on 05/08/20
9.40 -23.51%
on 06/19/20
+3.67 (+104.26%)
since 05/07/20
52-Week
1.74 +313.22%
on 09/03/19
9.40 -23.51%
on 06/19/20
+5.28 (+276.44%)
since 08/07/19

Most Recent Stories

More News
Angelman Syndrome Industry Outlook to 2030: Key Regional Market Projections and Epidemiology Forecasts

, /PRNewswire/ -- The drug pipelines has been added to offering.

OVID : 7.19 (+3.75%)
Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit,...

OVID : 7.19 (+3.75%)
Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome

-- Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing...

OVID : 7.19 (+3.75%)
Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe

and , /PRNewswire/ --

OVID : 7.19 (+3.75%)
Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe

- Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries...

OVID : 7.19 (+3.75%)
Ovid Therapeutics Added to Russell 2000(R) and Russell 3000(R) Indexes

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been...

OVID : 7.19 (+3.75%)
Ovid Therapeutics (OVID) Jumps: Stock Rises 12.4%

Ovid Therapeutics (OVID) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

OVID : 7.19 (+3.75%)
GMDA : 4.15 (-2.12%)
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food...

OVID : 7.19 (+3.75%)
Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases

-- Ovid to collaborate with renowned clinical and molecular geneticist expert, Wendy K. Chung, M.D., Ph.D.

OVID : 7.19 (+3.75%)
Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple presentations...

OVID : 7.19 (+3.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade OVID with:

Business Summary

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved...

See More

Key Turning Points

2nd Resistance Point 7.59
1st Resistance Point 7.39
Last Price 7.19
1st Support Level 6.90
2nd Support Level 6.61

See More

52-Week High 9.40
Last Price 7.19
Fibonacci 61.8% 6.47
Fibonacci 50% 5.57
Fibonacci 38.2% 4.67
52-Week Low 1.74

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar